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Abstract: Over a decade ago, nanotechnologists began research on applications of nanomaterials 
for medicine. This research has revealed a wide range of different challenges, as well as many 
opportunities. Some of these challenges are strongly related to informatics issues, dealing, 
for instance, with the management and integration of heterogeneous information, defining 
nomenclatures, taxonomies and classifications for various types of nanomaterials, and research 
on new modeling and simulation techniques for nanoparticles. Nanoinformatics has recently 
emerged in the USA and Europe to address these issues. In this paper, we present a review of 
nanoinformatics, describing its origins, the problems it addresses, areas of interest, and examples 
of current research initiatives and informatics resources. We suggest that nanoinformatics could 
accelerate research and development in nanomedicine, as has occurred in the past in other fields. 
For instance, biomedical informatics served as a fundamental catalyst for the Human Genome 
Project, and other genomic and –omics projects, as well as the translational efforts that link 
resulting molecular-level research to clinical problems and findings.
Keywords: biomedical informatics, nanomedicine, nanotoxicology, ontologies, electronic 
health records
Introduction
Recently, a consensus has begun to emerge about the informatics infrastructure needed 
to gather, curate, and share information among all the stakeholders in  nanotechnology. 
A more effective nanoinformatics infrastructure should allow for efficient and exten-
sive sharing of data, information, and knowledge about nanotechnology research and 
applications. In this review, we will initially focus on the medical applications of 
nanotechnology and their relationships to nanoinformatics. To avoid confusion with 
term usage, we use only the term “nanoinformatics” even though specific illustra-
tive examples may be referenced in the literature under “bio-nanoinformatics” or 
“nanomedicine informatics.” Finally, we will address other fields of application in 
nanotechnology with a discussion of the current directions and needs for developing 
a broader nanoinformatics infrastructure.
Existing capability: biomedical informatics
The use of computers in biomedicine began in the 1950s, with early applications in 
hospitals,1 and pioneering scientific computer programs for modeling the diagnostic 
 process.2 Somewhat later, computational biology emerged to tackle problems of scientific 
inquiry at the molecular level. The field of medical informatics gradually developed, 
and came to include areas such as computerized medical records; artificial intelligence 
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systems for medical diagnosis and planning; and laboratory, 
radiology, and hospital information systems.1 In compu-
tational biology, databases of macromolecular sequences, 
structures, and functions were developed and validated with 
experimental data.3 Later, the Human Genome Project (HGP) 
produced massive bioinformatics datasets, and the systems 
and software tools developed in the project were essential to 
the completion of the project ahead of schedule.4,5
Over the past decade, biomedical informatics (BMI) 
has continued to develop as a discipline encompassing both 
medical informatics and bioinformatics,6–8 based on a large 
number of research projects. These include over 1000 public 
databases containing –omics and disease information that 
are essential to biomedical translational research.9–14 The 
construction of ontologies such as Gene Ontology5 and many 
others15–18 provided well-defined terminologies and semantic 
content for data, information, and knowledge sharing among 
heterogeneous systems.
Despite the broad scope of application of BMI,  ranging 
from molecular medicine to public health, the field of 
nanomedicine19–21 has received scant attention. However, at 
the time of writing, almost 3000 references were retrieved in 
the PubMed database using the search term “nanomedicine.” 
This number increases daily.
Nanotechnology and nanoinformatics
The many different challenges of nanotechnology for nano-
medicine22,23 suggest the need for a new informatics area. 
In this biomedical context, nanoinformatics refers to “the 
use of informatics techniques for analyzing and  processing 
information about the structure and physico-chemical 
characteristics of nanoparticles and nanomaterials, their 
interaction with their environments, and their applications 
for nanomedicine.”24 The term was officially recognized 
after an initial workshop that took place in Arlington, VA, 
in 2007.25 This coincided with parallel activities launched 
at the same time in Europe with support from the European 
Commission.26
Nanoparticles roughly span the dimensions between 
1 and 100 nm. Below 1 nm, their behavior can be explained 
by known atomic, molecular, and ionic interactions and 
forces; above roughly 100 nm their properties become similar 
to the bulk properties of the material.27–29 Inside that range, 
a particle can exhibit new and variable properties due to 
quantum effects. In addition, particles , 100 nm may also 
exhibit enhanced bioavailability and transport in and through 
biological organisms, tissues, cells, organelles, membranes, 
and interstices.30–32 Historically, particles within this range 
have been defined as “ultrafine” particles and have long been 
the subjects of research regarding their health – and toxic – 
effects.31,32 Because new quantum effects or enhanced avail-
ability may also be evident as coating or layer thicknesses, 
surface variations, and/or pores fall into this size range, 
nanomaterials include larger materials that have nano-sized 
layer thicknesses or surface features. Finally, because the 
upper limit of the size range is somewhat arbitrary, other 
definitions are in use that extend the upper limit to 1000 nm – 
that is, to 1 µm.
Nanoparticles can be used as drug carriers and may alter 
a drug’s reactivity, strength, and, ultimately, its behavior 
in vivo.33–35 Advances in nanotechnology design and delivery 
can allow delivery of a drug to a targeted tissue, release of a 
drug at a controlled rate, treatments for drug detoxification,36 
or detection of the early stages of a carcinogenic process.37,38 
For instance, Doxil® and Abraxane® are two nanodrugs 
already approved and currently available.33 The unique 
 properties or “nano” characteristics of a nanomaterial – 
including size, shape, charge, biocompatibility, solubility – 
can be critical factors in enabling and facilitating important 
biofunctional goals like tumor penetration.39
Following Vélez and Vélez40 and Maojo et al,41 
we consider five main areas in nanomedicine to provide some 
relevant examples of applications. These areas introduce 
significant informational challenges.
Delivery systems
Nanoparticles (eg, dendrimers, liposomes, buckyballs, fuller-
enes) can be designed as carriers to deliver genes, drugs, or 
molecules and to target specific parts of specific organisms (eg, 
organs, cells, molecules). By building detailed models and in 
silico computerized simulations, it is possible to design their 
structure and predict their properties.42 Delivery mechanisms 
include controlled release times, release rates, and detection 
systems to monitor effects of the drug or provide feedback. 
Nanodelivery – where nano-sized objects are transported 
through the body, target specific cells, and penetrate through 
cell and nuclear membranes – can improve the bioavailability, 
biocompatibility, therapeutic efficacy, stability, and solubility 
of drugs.43–46 Viruses, for example, are nano-sized and have 
evolved to perform exactly those same functions.47 We can 
differentiate between passive nanodelivery agents and those 
that can be triggered on arrival at the action site. Nanodelivery 
agents are designed to improve the availability of a poorly 
soluble or otherwise toxic bioactive compound (savaged 
drugs). To understand the value of nanodelivery devices in 
modern medicine, we should consider that an effective drug 
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must satisfy many requirements, including being of low 
toxicity, being efficacious, specific, and soluble, before it 
can be considered a viable candidate for clinical trials. The 
staggering costs of developing a drug result from the need to 
satisfy all the requirements simultaneously. Recent estimates 
of the cost of designing a drug range between US$3000 
and 11,500 million.48 This constraint has resulted in the low 
number of primary drugs currently available. One of the best 
known examples of a nanodelivery agent is Abraxane®,49 a 
drug-polymer (albumin) blend that encapsulates paclitaxel in 
a polymer matrix that simultaneously increases the effective 
solubility of the paclitaxel while reducing the toxic effects 
of free paclitaxel.50
Nanodelivery agents are designed following a number of 
alternative chemical strategies, including covalent linking of 
bioactive drugs and homogeneous and heterogeneous encap-
sulation of the bioactive payload.51 Nanodelivery devices can 
be designed (eg, controlling the device size) or decorated 
(eg, adding specific markers – such as folic acid – or anti-
bodies) to target-specific sites.52 Sometimes, these targeted 
nanoparticles are combined with imaging agents that aid 
monitoring the evolution of the nanodevice in the patient’s 
body.53 Nanodelivery devices combining multiple function-
alities in a single scaffold are giving rise to a new generation 
of controllable platforms that can be activated using external 
sources (eg, laser heating).54 However, external triggering 
mechanisms have many limitations, including limited depth 
of penetration and possible side effects. Autonomous targeted 
nanodelivery agents (which could be understood as the sim-
plest conceivable nanorobots) will take full advantage of a 
nanoplatform’s technological capabilities by operating in 
deep tissues and even reporting the completion of the delivery 
process from within the site of action.
Nanoinformatics has a clear role in the scientific inquiry, 
design, and technological development of nanoparticle 
 production.55 Similarly, it can be associated with the  recording 
and analysis of experimental test results from the delivery of 
nanoparticles to different biomedical and ecological targets 
and contexts56 (eventually taking organism–microbiome 
interactions into account).
Implantable devices
Various types of nanodevices – nanorobots, for instance – can 
be designed for monitoring specific diseases.57–59 The field is 
still in its infancy, with existing prototypes showing proof of 
principle for targeted transport for biomedical applications. 
These devices can serve to mitigate toxicity by detecting 
modifications in biomedical parameters and releasing a drug 
under favorable conditions. The implantable device would 
require tailoring to a patient’s individual response by moni-
toring, for example, information related to the patient’s gene 
expression, proteome, and/or metabolome.41
Diagnosis and prevention
The interactions between nanoparticles and biological 
 molecules in living organisms may have properties that make 
them particularly useful for diagnosing specific  pathological 
conditions in certain diseases. For instance, luminescent 
nanoparticle quantum dots (QDs) can be engineered to bind to 
specific molecules, both in vitro and in vivo. The links between 
the in vitro and in vivo research can help in the diagnosis and 
therapy of major diseases47 such as cancer, cardiovascular 
diseases, respiratory diseases, and diabetes, as well as many 
other applications. Known biomarkers based on reported 
patient data can be correlated with disease pathology. This kind 
of decision support is an advanced area of research in BMI that 
can be extended very naturally to nanomedicine.20,39,60,61
Therapeutics
Nanotherapies can be less invasive than classical drug thera-
pies and may require lower dosage levels. Improvements in 
efficacy can help reduce the side effects of many current 
drugs as nano-based clinical trials have demonstrated the 
benefits of nanotherapies and evaluated their toxicity relative 
to existing formulations. The authors have participated in 
related research for almost a decade, in testing the potential of 
clinico-genomic integration for designing models of clinical 
trials in the new context of genomic medicine.62 Computer-
ized records, guidelines, and protocols must be designed 
for such nano-applications to integrate antimicrobial and 
antibacteriological  information. Linked to both simulation 
and clinical trial results, these nanoinformatics applications 
could help identify and  compensate for individual reactions 
to these pathogens and support the needed clinical 
guidelines.24,41,63
Materials
Many nanomaterials are particles or designed structures, 
rather than biomolecules. Some properties that make these 
nanomaterials useful for biomedical applications include 
enhanced mechanical, optical, magnetic, and electrical 
characteristics. Analytical studies carried out to determine 
the biological interactions between specific nanoparticles and 
cell physiology should help in the design of new nanomedical 
approaches.64 New biomaterials can also be used in implants 
for replacement therapy and in regenerative medicine.65
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Information on early research in nanomedicine primarily 
consisted of journal publications, results of workshops 
and symposia, and reporting in the public media on these 
and other innovations and their benefits and risks. Later, 
a broader agenda for nanoinformatics evolved as the field 
progressed. Better characterization of nanomaterial struc-
tures, their physico-chemical properties, and their in vitro 
and in vivo interactions was necessary.66,67 For example, the 
US National Cancer Institute (NCI) established the Nano-
technology Characterization Laboratory as an integral part 
of its Cancer Nanotechnology Plan. It was evident that better 
instrumentation was needed in the laboratory, factory, and 
field for experiment, production process control, and separa-
tion techniques. This was due to the wide variability in their 
internal structures, surface ligand distributions, impurities, 
and transformational changes such as protein coatings.
New positive and negative controls were needed for 
existing standard analytical methods. Similarly, new meth-
ods were needed to standardize newly emerging sensing, 
delivery, release, and imaging modalities. Quantifying data 
reproducibility, uncertainty, and error of these new or modi-
fied methods would require ruggedness testing and sensitivity 
analysis of the methods. As the field evolved, a demand for 
reference and study materials grew, both for interlaboratory 
testing as well as for consistent studies of material trans-
formation due to aging, handling, and contamination. In 
addition, it became evident that a nanomaterial registry was 
needed to provide unique identifiers for nanomaterials at the 
level of individual manufactured lots. The lot-to-lot property 
variations and libraries of well-characterized nanomaterials 
with controlled variations in their component structures were 
also needed to elucidate the correlation between the structures 
and their properties.
Finally, there was a need for an extensive, coordinated 
terminology for nanomaterials, their structures, and their 
properties. Such terminology would allow a more unam-
biguous interpretation of the accuracy and reliability of data 
developed by researchers in different disciplines and different 
material providers. The availability of standard materials and 
material libraries soon led to efforts to formulate quantita-
tive structure–activity relationships for these materials.68 
At the same time, more extensive modeling and simula-
tion was needed to provide a detailed understanding of the 
mechanisms of efficacy and toxicity. Similarly, it required 
an improved understanding of nanomaterials production, 
modification, transformation, and disposal – which could be 
met only through multilevel modeling. An ultimate goal for 
this activity was improving data quality both for experiment 
and modeling and simulation. In parallel, this would lead to 
improve risk-assessment capability for the design of nano-
material products and for evaluating their possible effects on 
the environment and human health and safety.66,67,69
State of the art and present 
challenges
The previous examples should be viewed from an informa-
tional perspective: is there a relevant role for informatics to 
support research, development, and translation in most of 
these nanomedical applications? Our answer is yes. Most 
of these examples included issues such as the development 
of large databases, device control, new biomedical imag-
ing modalities, computerized decision support systems, 
the management and exchange of enormous amounts of 
heterogeneous data and knowledge, and/or creating models 
and simulators for characterizing nanoparticles and their 
efficacy and toxicity. Examples of nanomedical applications 
are now increasing rapidly in scientific publications such as 
the International Journal of Nanomedicine (which is nearing 
its first 1000 papers at the time of writing).
A major problem is that the science of nanomaterial–
biological interactions is still at a very early stage. This means 
that we do not know yet how to engineer nanoparticles to 
minimize toxic effects in animals and on the environment. 
Modeling and simulation are essential here. Data  mining of 
large databases of results from in vitro and in vivo experiments 
will be needed to help predict their possible side effects – as 
mentioned above. Nanoinformatics methods will be central to 
integrating many different  methodologies involving discrete 
and continuous modeling, design,  simulation, experimenta-
tion, visualization, and interpretation techniques. All this 
should improve our understanding of the risks presented by 
nanomaterials.
A systematic nomenclature for nanoparticle formulations 
and characterization is sorely needed for improving clarity 
and standardization in searching, locating, and comparing 
data on specific nanostructures within large preclinical and 
clinical databases. At the same time, the development of such 
a nomenclature would involve text mining of the complex 
scientific literature. Current approaches are based almost 
entirely on simple statistical associations among short seg-
ments of text. The use of novel, “visual” nano-ontologies could 
provide greater semantic content, together with research on 
more advanced methods of text mining from the literature. 
As mentioned, the choice of unique material identifiers is an 
important subtopic of ongoing research by the new Nanoma-
terials Registry supported jointly by the NCI, the National 
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Institute of Environmental Health Sciences, and the National 
Institute of Biomedical Imaging and Bioengineering.70 The 
registry has developed a prototype database and user interface 
and initial datasets are being curated.71 A related important 
issue is that of equivalency – that is, the determination of 
whether two nanomaterials are essentially the same.
In all the –omics fields, the need to transfer basic research 
from the lab to the bedside is a fundamental challenge. The 
American Medical Informatics Association sponsors the 
American Medical Informatics Association Summit on 
 Translational Bioinformatics, which aims to translate the latest 
basic research results in the –omics areas into new knowledge 
for personalized medicine.72 We have also suggested a new 
subfield, which we called “translational nanoinformatics,”24 
aimed at translating basic nano-level research into clinical 
applications.73 In this context, research results – and side effects, 
such as nanotoxicity, which is a major clinical concern – can 
help develop insights into how in vitro and model results can 
be transferred to clinical situations and practice.
To achieve such ambitious goals, professionals will need 
to draw on organized international networks of research-
ers, projects, and laboratories. These networks would 
enable people with related objectives to exchange data and 
resources and to establish collaborative initiatives. Broader 
and stronger collaborations between researchers worldwide 
will stimulate synergies that can accelerate research and help 
minimize nonproductive duplication of efforts (and pos-
sibly funding). Human and other genomic, proteomic, and 
metabolomic projects have provided telling examples of the 
advantages of openly sharing data and software resources. 
Such open strategies need to be considered, with appropri-
ate adaptations for nanotechnology and nanomedicine – for 
instance, to accommodate proprietary issues associated with 
engineered nanoparticle design, production, and use.
Challenges for informatics  
in nanomedicine
As suggested previously, due to lack of information, the 
major research challenges and requirements include:
•	 new reference nanomaterials
•	 improved nanomaterial characterization as reported in 
the literature and in databases
•	 determination of the sensitivity of the analytical methods 
to variations in experiments, materials, and methodologi-
cal approaches
•	 quantifying the error and uncertainty in the methods and 
protocols used to produce the data
•	 evaluation and management of various types of risks.74,75
One of the earliest papers (2004) using the term 
“nanoinformatics,” had already pointed out some of the 
challenges that this area should address.76 Bioinformatics 
had evolved to solve problems related to data management 
in topics such as gel electrophoresis, amino acid sequencing, 
polymerase chain reaction, and gene mapping techniques.77 
Meanwhile, nanoinformatics needed to address two main 
issues: (1) data results from nano-level experimentation, 
which lead to large and constantly changing sets of vari-
ables due to the  continual growth of scientific knowledge; 
and (2) the need for control of the systems themselves. 
Further, the  elements that the researcher aimed to manipu-
late dramatically increased the complexity of the research 
equipment itself and the refinement of the experiments. 
All of these required the processing and analysis of mas-
sive datasets, with complex calculations needed to manage 
 computerized models at the atomic, molecular, and nano 
levels. The subsequent development of ever-increasing 
applications of nanotechnology and nanomedicine has 
uncovered many different problems that benefit from or 
require nanoinformatics techniques.
Various US agencies have already formulated recommen-
dations for nanoinformatics. For instance, the Presidential 
Council of Advisors on Science and Technology provided a 
key recommendation in 2010 about nanoinformatics:  “Support 
wide distribution and availability of new non-proprietary 
information about the properties of nanomaterials.”78 Later, a 
group of scholars issued a roadmap identifying various chal-
lenges and proposing a research and development agenda.79 
Similarly, the European Commission funded a support action 
called ACTION-Grid. ACTION-Grid, comprising groups of 
scholars from Europe, the USA, Latin America, and Africa, 
produced a white paper identifying the connections between 
BMI, grid computing, and nanoinformatics.80 Several of the 
authors of this paper participated in all three initiatives men-
tioned. A fourth document has been recently released entitled 
A Research Strategy for Environmental, Health, and Safety 
Aspects of Engineered Nanomaterials, by the Committee to 
Develop a Research Strategy for Environmental, Health, and 
Safety Aspects of Engineered Nanomaterials of the National 
Research Council.81
The main challenges proposed by the latter three of these 
groups79–81 are shown in Table 1.
Successful implementation of informatics strategies – 
including ontologies, data sharing, and model development – 
requires appropriately annotated and curated datasets. As can 
be determined from these four reports, nanoinformatics, in 
contrast with the more developed field of bioinformatics, 
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Table 1 Nanoinformatics challenges proposed by three recent initiatives
Nanoinformatics 2020 Roadmap (2010)79 The ACTION-Grid White Paper (2010)80 A Research Strategy for Environmental, 
Health, and Safety Aspects of Engineered 
Nanomaterials (2012)81
Nanomaterial data gap workshops for discussing 
how to facilitate the exchange of data and  
information about engineered nanomaterials:  
their physicochemical properties, behavior in  
the environment, biological activity, etc
Creation of a nanoinformatics infrastructure to 
collect, curate, annotate, organize, and  
archive the available data
Identify minimum characterization principles  
to develop standardized descriptors  
(that is, metadata) for engineered 
nanomaterials (ENMs)
Development of a meta-ontology for  
nanoinformatics from existing ontologies  
and structured databases, dealing with issues  
such as interoperability and federation and  
demonstrating its applicability across multiple  
domains
Design of extended web nano portals, linking  
groups and information around the world to  
facilitate data sharing
Establish uniform metadata to describe ENM 
manufacturing and distribution processes 
and to correlate lot-to-lot variability of ENM 
properties
Minimum information recommendations:  
minimal information required for nanomaterial 
characterization, quality assurance processes  
for data collection and curation, ranking  
system for quality and completeness of  
data/datasets
Development of repositories/databases of  
use cases, resources, nanotoxicity data and,  
clinical trial experiments or on nano facilitating  
the reuse of data – such as  
ArrayExpress for genomic data
Develop ontologies and data formats to allow 
relevant data on gene and protein expression 
to be correlated with ENM toxicity mechanisms 
and, in particular, to develop an ontology 
“crawler” to aid in mapping relationships among 
ontologies
A meta-crawler for searching nano-related  
information on the web, serving as an  
interface to relevant ontologies (browse and  
search), resources (semantic search), materials 
(structural search), literature (links back to  
relevant terminologies), and news
Incorporation of regulatory aspects:  
standards, issues related to open data  
and source tools, quality control
Develop strategies for federating 
nanotechnology databases to allow seamless 
data exposure and data sharing while 
protecting intellectual property rights
Simulation challenge: development of simulation 
and modeling tools for nanotechnology,  
targeting specific materials and using standard  
nanostructures that are well characterized to  
compare and validate calculation tools
Translational nanoinformatics: linking basic  
research from the lab to the bedside and  
nano-information to the Electronic  
Health Record
Develop new mechanisms for digital archiving 
and annotating and updating of methods, data, 
tools, and models to spur rapid and efficient 
formation of new targeted national and 
international scientific collaborations
raises some very special challenges. Biopolymers are often 
discrete structures or sequences, whereas nanomaterials 
typically exhibit a dispersion of sizes, compositions, and 
surface coatings. Such dispersions are difficult to define 
and reduce to the precise codes typically needed to classify 
and describe objects and their interactions in informatics 
 modeling. Second, given the wide array of nanomaterial types 
and their as yet largely unknown interactions within different 
tissues and organismal physiologies, analytic measurements 
to make direct comparisons will be difficult to “anchor” to the 
appropriate experimental and clinical contexts. Informatics 
approaches will need to synthesize the information from 
multiple techniques to describe different nanomaterials. Such 
advances could help to overcome the many gaps in data and 
knowledge that describe nanomaterials in the literature, since 
most materials are as yet incompletely characterized.
It is worth noting the concurrence among the three dif-
ferent reports summarized in Table 1. This perspective is a 
significant acknowledgement that informatics technologies 
must become more central and more integrated with other 
scientific technologies and practices.82 This change may owe 
a great deal to the successful implementation of  informatics 
in facilitating progress in genomics, proteomics, and 
 metabolomics. The eventual goal of developing “intelligent” 
feedback processes – seen as a human–machine interaction 
that can incorporate learning from past experiments – among 
inquiry, design, testing, and refinement of bioparticles, can 
only be achieved with the intermediation of novel nanoin-
formatics techniques that include: modeling, a wide range 
of relevant simulations, and the sophisticated analysis and 
interpretation of massive experimental datasets. This objec-
tive goes beyond what is currently achieved with simple data 
mining, even in network science environments.24,81,83
In the next section, we comment on various areas that 
we consider the most challenging for nanoinformatics 
research.
Nanoinformatics areas
Over the last few years, the growing nanoinformatics commu-
nity has begun to focus on an increasing number of research 
topics that could accelerate developments in nanomedicine. 
A nonexhaustive list of significant examples follows.
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Data, ontologies, and exchanges  
of information
The need to develop new data, information, and knowledge 
repositories, and create methods for information exchange 
in nanomedicine is growing rapidly. Developing biomedi-
cal ontologies, essential to the semantic web, is a current 
approach for facilitating data exchange through common 
terminological references.84 Biomedical ontologies describe: 
concepts or classes – for instance, animals, organisms, 
organs, cells, molecules, proteins; their associated 
properties; semantic relationships and specific instances 
– elements, such as a specific cell or protein; and logical 
formalisms to interrelate the terms, properties, and instance 
relationships. Ontologies have been essential for managing 
and systematizing information and knowledge, particularly 
in the biomedical field.85 Ontologies are currently essential 
in facilitating system interoperability and information 
mapping, search, retrieval, extraction, and multilevel data 
integration.86
Two nano-related taxonomies or ontologies have already 
been reported: the Nanomedicine Taxonomy87 and the 
NanoParticle Ontology.88 In addition, there are proposals to 
develop domain ontologies, vocabularies, and taxonomies 
for topics such as cancer nanotechnology, with support from 
the NCI and other organizations. The NCI’s white paper83 
reports various initiatives, such as an ontology for new 
nanomaterials, an atlas of nanotechnology, and the Nanotech 
Index Ontology, among others.
The authors have carried out extensive research on system 
interoperability for biomedicine. These include syntactic 
and semantically focused approaches that use ontologies 
as conceptual references to overcome classical problems of 
database integration.89 The original focus in the last decade 
was on integration for –omics and systems biology research 
linked to clinical information, which can be adapted to 
address multilevel integration down to the nano level. There, 
it would need to include, for instance, the development of 
large repositories of nanoparticle information or new nano-
ontologies – both textual and visual, including information 
about the shapes and volumes of structures involved in nano-
level interactions. Various US research groups and labora-
tories have worked on related activities, such as the Cancer 
Biomedical Informatics Grid (caBIG®)90 and caNanolab (see 
Appendix). By way of example, Stokes et al91 developed an 
integrated information management system for personalized 
oncology, which is an “intelligent” information system for 
data management and interpretation that also supports the 
implementation of clinical applications.
As stated elsewhere,81,83 there is a significant need to 
develop an informatics portal with facilities analogous to 
those used in conjunction with the Protein Data Bank. Such 
a portal should focus on structural models of nanomaterials 
to be stored, described, curated, validated, and exchanged. In 
addition, predictive and probabilistic models and submodels 
could be made available to developers and users through 
this portal to complement new experimental techniques and 
theoretical approaches.
Imaging
QDs are semiconductor luminescent probes for many bio-
medical applications.92,93 Their various characteristics include 
small size (around 10 nm in diameter), high photostability, 
specific adjustable or selectable optical and electronic prop-
erties, size-tunable light emission, superior signal bright-
ness, resistance to photobleaching, and broad absorption 
spectra for simultaneous excitation of multiple fluorescence 
colors and multimodality to facilitate in vivo diagnosis – 
for example, for various types of cancer.21,92,93 They can be 
attached to targeted molecules within malignant tumors, 
facilitating early diagnosis and therapy, aimed at improving 
patient outcomes.
Along this line of research, many other materials are 
entering clinical trial.94 Lanza et al95 have developed a nano-
particle magnetic-resonance-imaging contrast agent that binds 
to blood vessels appearing with early tumor development. 
In vivo molecular imaging capabilities will enable optical 
biopsies, with tumors being typed and staged at the time of 
detection.95,96 More complete molecular characterization of 
lesions can enable physicians to recognize and prevent chemo-
resistance. Advanced imaging combined with traditional 
surgical techniques for intraoperative guidance will make 
improved resections of cancerous tumors possible.39
Similarly, targeted gold nanoparticles can improve 
molecular computed-tomography (CT) imaging of cancer.97 
Various reports97,98 have suggested the feasibility of cancer 
diagnosis in vivo by using molecular markers rather than 
anatomical structures, through better visualization by clini-
cal CT. With nanoparticles, CT can go beyond its present 
structural imaging capabilities by adding functional and 
molecular-based imaging capacities as well. For instance, 
various types of nanoprobes have been developed as blood 
pool CT contrast agents, such as gold nanoprobes and 
nanotags, iodine-based emulsions, and tantalum oxide 
nanoparticles.97
Imaging techniques based on nanotechnological research 
would be less invasive and more precise than existing 
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 methods in biomedical imaging. For example, QDs generate 
signals of long duration that can be used to improve image 
quality. Advanced informatics methods could then link tis-
sue banks with images of tissues and histology results to 
provide enhanced image annotation down to the nano level. 
The images could also be linked to electronic health records 
as needed.
Modeling
Molecular modeling and simulation techniques are central 
to systems biology research. In the nano world, they will be 
the key to the bridging of nano-level effects with aggregated, 
molecular, cellular, tissue, organ, and organismal system 
level effects. Quantum mechanics, molecular modeling, and 
simulation techniques provide the scientific basis for analyz-
ing and understanding the basic physical, chemical, and bio-
logical properties of nanoparticles and nanomaterials.99 Their 
results provide new insights about their specific interactions 
with biological systems. Computer-intensive methods like 
hybrid quantum mechanic and molecular dynamic simula-
tions facilitate the characterization of nanoparticle properties. 
This also provides substantial information about biological 
phenomena related to the interactions between nanoparticles 
and physiological systems,100 exploring interactions at dif-
ferent scales. Through these simulations, one can study the 
fundamental physico-chemical properties of nanoparticles. 
High-performance computing infrastructures – such as grid, 
cloud computing, or dedicated supercomputers – can help 
accelerate this work.
Bewick et al101 have reported on the complexity arising 
from the inherent characteristics of natural biological 
systems. These include their heterogeneity, their multiscale 
space–time interactions, the noise generated in physical 
systems at the nanoscale, the strong coupling between 
processes that occur at different scales, and the challeng-
ing dimensionality size of data needed to represent typical 
biological systems.101
Jaramillo-Botoro et al102 have suggested the typical 
components of a nanomedical model in terms of a five-level 
theoretical hierarchy: (1) quantum mechanics to determine 
electronic states, (2) force fields that result from averaging 
the electronic states and thereby obtaining atom-based forces, 
(3) simulations of atomic interactions based on force fields, 
(4) mesoscale or course-grained descriptions that average over 
many atoms, and (5) continuum mechanics using distributed 
properties for membranes, cells, tissues, and organs.
As in other biomedical and engineering areas, if 
insufficient complexity is assumed, the descriptions will not 
be adequate or accurate for representing the phenomena. 
However, if too much complexity is assumed, mathematical 
models may prove too complex to be useful from a practical 
perspective. According to Bewick et al,101 the challenges for 
nanobiosystem modeling are twofold. First, we must develop 
improved techniques for dealing with nanoscale biological 
complexity from a computational perspective. Second, we 
need to understand the role of biophysical and chemical 
complexity itself in nanobiosystem behavior.103
In this regard, there is no Protein Data Bank-like 
entity to develop, validate, and curate nanoparticle or 
 nanomaterial structures – except the Collaboratory for 
Structural  Nanobiology.104 This modeling cannot be done 
without  several different layers of structural modeling. It is 
not possible to discover structure–property relations unless 
we already know the structural motifs of interest, for which 
researchers need to build enough knowledge across different 
platforms. Thus, modeling must be linked to what we have 
mentioned already regarding the need to establish networks 
of researchers. The latter can collaborate by sharing both 
structural and predictive models, which will be essential to 
accelerate research and translation to clinical practice.81
Data and text mining for nanomedical 
research
Over the past decade, the authors have carried out an 
extensive examination of text mining research, particularly 
for bioinformatics problems.105–107 We later discuss some 
examples of the authors’ research in this area.
Using data mining approaches, researchers try to 
extract, confirm, or discover new knowledge from large 
databases. Data mining was traditionally used in large 
medical and biological databases to generate or confirm 
research hypotheses. Their application has been funda-
mental for extracting knowledge patterns – for example, 
decision trees or association rules – either for descriptive or 
predictive tasks. Most of these tasks are based on inductive 
approaches. In the context of nanobiology, for instance, it 
is possible to use various mining strategies for predicting 
the potential effects of engineered nanomaterials (ENMs) 
based on their chemical properties, their mechanisms of 
action and the biological pathways involved. This requires 
standardized data collection and warehousing of very 
diverse sets of data and metadata types and formats.81 
This means that adequate informatics infrastructure will 
be essential to facilitate storage and data sharing of mul-
tilevel data related to research, development, translation, 
and regulation.
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From a public health perspective, biostatisticians and 
epidemiologists can monitor the impact of nanomedical 
applications by carrying out surveillance studies of nano-
enabled drugs to monitor their potential toxicity as well as 
effectiveness in clinical practice.46,60 In the era of personalized 
medicine – usually referred to as “genomic medicine,” even 
though nanomedicine is already transforming this character-
ization – professionals and researchers must study and assess 
the use of nanomedical treatments for specific patients, based 
on individual features.
Clinical trials and toxicity
Nanomedicine will require new approaches to medical 
care and clinical trials, which are focused on testing their 
efficacy but weigh the potentially deleterious side effects of 
nanoparticles.94,108–110 As Lai110 and Adiseshaiah et al111 have 
suggested, the potential hazards of nanomaterials must be 
evaluated by conducting in vitro high-throughput assays and 
mechanistic studies and comparing the data obtained from the 
latter with available reference data. Hazard identification of 
nanoparticles and their effect on humans has been conducted 
for several ENMs using in vitro and in vivo methods.112 
Complementary research on the toxicity of nanomaterials and 
its impact on environment research can be also carried out, 
focusing on understanding toxicity mechanisms of ENMs. 
Additional information is needed to analyze the pathways 
of biochemical responses to ENMs and how to obtain data 
from adverse outcomes.
Important factors influencing nanotoxicity are size, 
shape, particle surface, biopersistence, surface chemis-
try, chemical components, dosage, free-radical produc-
tion, and release of toxic ions through dissolution in 
biological media.108,110 Nanoparticles can also interact 
with the immune system, provoking other side effects in 
humans.113
All these analyses will produce datasets that can inform 
the design and construction of computational models and 
simulations that will attempt to predict the toxicity of 
nanoparticles. Nanoinformatics must help to design and 
implement predictive models characterizing the interac-
tions involved in nanoparticle exposure, the aggregate and 
cumulative hazards, and the health and environmental risks 
on various tissues and body organs and systems. Data must 
be coherently organized, shared, and integrated to allow 
effective data mining and to explain observed patterns of 
nanotoxicity. In the section entitled Examples of applications, 
we provide research examples of how nanoinformatics and 
nanotoxicity can be related.
For nanomedicine to become practical, toxicity information 
must be available to physicians and included in computerized 
medical records. There are public databases of toxic effects 
such as the Nanoparticle Information Library (http://
nanoparticlelibrary.net/index.asp) created by the National 
Institute for Occupational Safety and Health and administered 
by the Oregon Nanoscience and Microtechnologies Institute 
(ONAMI), and the Nanomaterial-Biological Interactions 
(NBI) Knowledgebase (http://nbi.oregonstate.edu/analysis.
php) hosted by ONAMI.
Standards
For BMI, a large number of standardized nomenclatures, 
vocabularies, coding standards and terminologies, such as 
the Health Level Seven International, Logical Observation 
Identifiers Names and Codes, Systematized Nomenclature 
of Medicine, Digital Imaging and Communications in Medi-
cine, and the tenth revision of the International Classification 
of Diseases, need to be extended to add concepts and links 
to nano-related information. The Unified Medical Language 
System, produced by the US National Library of Medicine 
is set to incorporate biological vocabularies and ontologies – 
like Gene Ontology5 – to link clinical- with molecular-level 
information. To this could be added nanomedical concepts 
and links that expand the current scope of biomedicine 
towards the nano level. For instance, nanomaterials require 
similar types of naming conventions – common and sys-
tematic names, computable representations of structures or 
open-source Chemical Abstracts Service registry number-
like codes-for linking data from many sources.108
Nanotechnological research and development requires 
a comprehensive development pipeline from nanoparticle 
synthesis to characterization, including in vitro and in vivo 
empirical approaches. This leads to clinical applications of all 
the materials and processes involved. For such a substantial 
requirement, nanoinformaticians must design and develop 
methods and build software tools to access, share, and inte-
grate a large amount of disparate information. As mentioned 
by Baker et al,83 the integration of these data, methods, and 
knowledge is likely to become a central challenge for nanoin-
formatics. For this, the prior experience of similar challenges 
in BMI may prove very helpful.
An example of such building upon existing biomedical 
systems for nanoinformatics is the Investigation, Study, Assay 
(ISA)-Tab file format,114 which shares common “Investiga-
tion” (the project  context), “Study” (a unit of research), 
and “Assay” (analytical measurement) metadata categories. 
The extensible,  hierarchical structure of this format enables 
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the representation of studies employing one or a combi-
nation of technologies, focusing on the description of its 
experimental metadata (ie, sample characteristics, technology 
and measurement types, sample–data relationships). ISA-
Tab standards and their extension to the nano level in 
ISA-TAB-Nano will allow the same standard formats for 
high-throughput screening, nanomaterial characterization 
data (physico-chemical, in vitro, and in vivo) and, possibly, 
in silico data as well.
Another significant example involves the development of 
standards for the minimum information required to character-
ize nanomaterials115 – which extend previous efforts carried 
out for microarrays – and for harmonization of formats for 
data sharing.
Impact
The amount of information on nanoparticle toxicity is 
increasing, suggesting that a wide range of characteristics 
may mediate and determine the scale, dynamics, and health 
and environmental impact of adverse effects – and of current 
therapeutics. Initial results, from both animal studies and 
in vitro experiments, suggest that the type, size, and mode 
of utilization of nanoparticles may produce different effects 
on cell cultures.116 Understanding the toxicity mechanisms 
and effects of nanoscale materials – nanotoxicology – is 
the most critical problem now faced by nanomedical 
 technology. The need for managing this information and 
linking it with specific patient data follows directly. There 
are various nanoscale materials for biological application 
that have failed because of their toxicity.45,109,110 This failure 
is due to the complexity of living organisms, which makes it 
difficult to predict the consequences (ie, adverse reactions) 
of inserting a material into biological systems: the toxicity 
of some nanomaterials involves very complex pathways as 
well as specific interactions between biological tissues and 
synthetic materials and the transformations those materials 
may undergo. All these issues point to the need for diverse 
informatics methods and tools to augment basic research 
results and bring together information from all relevant lines 
of research and clinical tests. Annotating the literature pres-
ents considerable challenges both in theory and in practice. 
For instance, to alert researchers as to whether a particular 
nanomaterial has been sufficiently characterized, whether 
the methods used to characterize the nanomaterial and its 
interactions were validated, whether the models used were 
appropriate, or whether invalid conclusions might have been 
drawn. As mentioned, we are carrying out research on some 
of these issues.
We summarize different aspects of nanoinformatics 
and its relevance to international research in Figure 1. In 
this figure, the various areas on which nanoinformatics can 
have a tremendous impact in the future are shown. We have 
 classified these potential impact areas into eight categories: 
(1) industrial, (2) economic, (3) international collaboration, (4) 
national policy, (5) informatics, (6) societal, (7) educational, 
and (8) scientific. For expanded information on these topics, 
The ACTION-Grid White Paper is publicly available.80
A pervasive nanoinformatics problem is poor quality 
of available data, especially in terms of its reliability and 
reproducibility. This is due to various reasons, including:
•	 the lack of development and utilization of validated 
methods for characterization of the nanomaterials and 
their properties
•	 the incomplete characterization of nanomaterials and the 
lack of reference material to be used in the assays; the 
lack of curation and annotation of available data so that 
a measure of its reliability can be provided
•	 the need for training materials for standard assays; the 
rise of multiple silos for nanotech data
•	 the problems in federating those silos into a searchable 
system
•	 the integration with –omics and system biology data
•	 and the need for a set of ontologies that allows mapping 
and navigation among different ontologies for different 
disciplines through a harmonized system of concept 
definitions.
A key issue is that nanoinformatics should not be 
just a support technology but a fundamental approach to 
integrating the various areas of research and translation 
needed for the field within a reasonable time. The diverse 
nano products cannot succeed without better characteriza-
tion, validated methods, better training, and informatics 
systems that permit practitioners to cope with the massively 
large amount of information needed to properly utilize the 
technology. This is an urgent need. How will a practic-
ing physician cope with all the different tests, treatment 
options, massively complex diagnosis decision aids, and 
so on, without informatics systems? Nanotechnology offers 
the hope of developing and testing these systems now so 
that we develop flexible methods of expanding them as our 
knowledge grows. Finally, researchers, designers, clinicians, 
practitioners, information brokers, and regulators face a 
critical issue of coping with a myriad of large information 
sources, for which nanoinformatics methods and tools are 
absolutely necessary. On balance, the persistence of prob-
lems within the entire scientific community should also 
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be  considered – as discussed in a December 2011 special 
issue of the journal Science on data reproducibility.117 In 
this sense, nanoinformatics could be a demonstration of 
how to enhance data and model reproducibility in other 
scientific fields.
It is yet unknown whether the cost of research and 
development in nanomedicine will significantly increase 
the cost of biomedical research. In this regard, some posi-
tive effects can be anticipated. For instance, nanoparticles 
could rescue or save from neglect failed or inappropriate 
drugs for which most of the biomedical research has already 
been done or they could be used for regenerative medicine.83 
Similarly, the scientific and technological opportunities for 
BMI–nanoinformatics interactions are many.
Educational and ethical aspects of nanomedicine will 
be a key issue for nanoinformatics, too. Nanotechnologists 
are often people with backgrounds in chemistry, physics, 
and engineering. For nanoinformatics (and nanomedicine), 
people with expertise in informatics, medicine, biology, 
pharmacy, and other fields will be necessary. Future programs 
and degrees in nanomedicine – and nanoinformatics – will 
have to incorporate a much broader range of research to 
address the multidisciplinary types of questions involved. 
Finally, nanoinformaticians – in analogy to what has been 
proposed for biomedical informaticians by scholars such as 
Mark Musen – will have to act as “information brokers,”118 
connecting people with different scientific backgrounds and 
interests.
Ethical issues
Nanotechnology and nanomedicine present important ethical 
issues, such as nanotoxicity, in terms of the organisms and the 
environment they try to control.119 A recent review concludes 
that none of the ethical questions surrounding nanomedicine 
are new or unique and that they would hold true for any new 
medical device or medicine that is being evaluated.74 The shift 
to nanomedicine creates a significant increase in technology 
use, which might change current clinical practice. On the 
contrary, Sandler75 argues that nanomedicine is more closely 
linked to ethics than to risks, since it raises a broad range of 
unique ethical issues. These issues will have also an affect 
on public health.60,120
New industrial areas of development
New informatics techniques may allow
new companies and academic settings to
work on nanotechnology and nanomedical
research, without the large budget
resources that are ususally necessary for
traditional research in the area
Enormous financial importance,
with exponential growth in
terms of investment and
revenues.
European groups can be funded






Opportunities for new research programs might
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the involved areas.
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and nanoinformatics objectives,
methods and tools that can be shared,
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Figure 1 Impact of nanoinformatics in different topics, modified from an earlier version presented by the authors in The ACTION-Grid White Paper.80
Abbreviations: AMIA, American Medical Informatics Association; BMI, biomedical informatics; EFMI, European Federation for Medical Informatics; IMIA, International 
Medical Informatics Association; ISCB, International Society for Computational Biology; NSF, National Science Foundation; US NIH, National Institutes of Health.
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Examples of applications
If we search for the term “nanoinformatics” in PubMed, only 
a few references are available at the time of writing – and 
most by the authors themselves. There are several reasons 
for such a result. First, the term “nanoinformatics” is quite 
new, and its use is slowly expanding. Second, many computer 
applications have been developed for  nanotechnological and 
nanomedical applications, but they have not been listed or 
published under the umbrella of the term “nanoinformatics.” 
Finally, the concept of nanoinformatics as an interdisciplin-
ary field, with research and results that can lead to advancing 
the scientific basis of nanomedicine and its developments, 
has not yet been widely adopted. That is, nanoinformatics 
has not yet been recognized as a field in which original and 
independent work can be carried out.
In this section, we give some examples that fully conform 
to “nanoinformatics” as characterized in this paper. They are 
related to information retrieval, text mining for locating nano-
toxicity information in the literature, and visual ontologies.
Information retrieval
We have recently developed an automated text indexing and 
retrieval engine that links scientific articles to concepts from 
the NanoParticle Ontology88 and the Foundational Model 
of Anatomy.121 The indexing engine was built following a 
dictionary-based approach, similar to that adopted by Garten 
and Altman.122 With the search engine, users can search for 
papers reporting which nanoparticles are more suitable for 
delivering a certain drug to a given anatomical location, or 
for identifying which nanoparticles are toxic to a specific 
Figure 2 Screenshot of the Nanoparticles Toxicity Searcher, using “quantum dots” as an example.
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Table 2 Important events in the nanoinformatics field over the past 5 years
Nanoinformatics events and activities Date
Past
Launch of the first version of the caNanoLab Portal, a research framework for biomedical nanotechnology data sharing.  
National Cancer Institute
March 2007
Nanoinformatics workshop. Arlington, VA June 2007
Launch of NanoMedNet, a platform for education and training in nanomedicine for medical professionals August 2007
The Network for Computational Nanotechnology receive a grant of USD$18.25 million from the National Science  
Foundation to support the nanoHub project, focused on computer simulation at the nano level
September 2007
Establishment of NanoSafe Inc, Virginia Tech Corporate Research Center’s Knowledgeworks Business Accelerator October, 2007
Research Challenges for Nanomanufacturing Systems. Arlington, VA February 2008
Launch of NanoImpactNet, a multidisciplinary European network on the health and environmental impact of nanomaterials April 2008
Launch of ACTION-Grid, first European initiative on Nanoinformatics June 2008
NSTI Nanotech Conference organized by Nano Science and Technology Institute (NSTI). Boston, MA
Launch of the International Alliance for NanoEHS Harmonization at Nanotox 2008 Conference. Zurich, Switzerland September 2008
Launch of the first working version of the NanoParticle Ontology. NCI Cancer Biomedical Informatics Grid (caBIG®) 
Nanotechnology working Group
December 2008
Publication of the white paper Ontologies in cancer nanotechnology research. caBIG, National Cancer Institute January 2009
Publication of the white paper The need for minimum information standards for development and advancement of  
nanomaterials as cancer diagnostics and therapeutics. caBIG, National Cancer Institute
February 2009
Publication of the white paper Nanotechnology Informatics White Paper.83 caBIG, National Cancer Institute
Nanotech Conference and Expo 2009 organized by NSTI. Houston, TX May 2009
1D Heterostructure Tool, new tool for the simulation of heterostructures at the atomic scale
Launch of GoodNanoGuide, an Internet-based collaboration platform about handling nanomaterials in an occupational  
setting. International Council on Nanotechnology (ICON)
June 2009
Inclusion of Medical Nanoinformatics in the “Recommendations of the International Medical Informatics Association (IMIA)  
on Education in Biomedical and Health Informatics”
January 2010
Synergies in Nanoscale Manufacturing and Research workshop. Ithaca, NY
Report to the President and Congress on the Third Assessment of the National Nanotechnology Initiative. President’s  
Council of Advisors on Science and Technology (PCAST)78
March 2010
Nanoinformatics publication in Pediatrics Research (first in a medical journal) by Maojo et al “Nanoinformatics and  
DNA-based computing: catalyzing nanomedicine”24
May 2010
Development of nano-TAB as ASTM standard (ASTM wK28974) initiated, standard for identifying nanomaterials and  
characterizations in a tab-delimited format
NanoTech Conference and Expo 2010. Anaheim, CA June 2010
Launch of the Collaboratory for Structural Nanobiology. National Cancer Institute and University of Talca
Publication of the National Nanotechnology Initiative Signature Initiative: Nanoelectronics for 2020 and Beyond July 2010
Publication of The ACTION-Grid White Paper on Nanoinformatics.80 ACTION-Grid Consortium,  
approved by the European Commission
September 2010
Destination Nano! Premier nanomanufacturing Conference, UMass Lowell. Lowell, MA
Launch of the Nanoscience Portal. National Science Foundation
“Nanoinformatics: making sense out of nanotechnology information.” International Council on Nanotechnology
Publication of the report Nanotechnology Research Directions for Societal Needs in 2020. National Science Foundation
5th General Assembly and Annual Forum of the European Technology Platform on Nanomedicine. Milan, Italy October 2010
Nanoinformatics 2010. Arlington, VA
Nanoinformatics review in Methods of Information in Medicine by de la Iglesia et al, “International efforts in  
nanoinformatics research applied to nanomedicine”
November 2010
Nanotechnology Innovation Summit, washington DC. National Nanotechnology Initiative December 2010
Establishment of QNano, integrated hub to support Europe’s nanosafety research community February 2011
Publication of the National Nanotechnology Initiative Strategic Plan. National Science and Technology Council
Publication of the Nanoinformatics 2020 Roadmap.79 National Nanomanufacturing Network April 2011
5th Concertation and Consultation workshop on Micro-Nano-Bio-Convergence Systems 2011. Mondragon, Spain
Nanoinformatics publication in Biological Research by González-Nilo et al, “Nanoinformatics: an emerging area  
of information technology at the intersection of bioinformatics, computational chemistry and nanobiotechnology”
May 2011
Publication of the Materials Genome Initiative Report Materials Genome Initiative for Global Competitiveness.  
National Sciences and Technology Council, washington DC
June 2011
NanoTech Conference and Expo 2011. Boston, MA
Nanoinformatics publication in Wiley Interdisciplinary Reviews, Nanomedicine and Nanobiotechnology by Thomas et al,  
“Informatics and standards for nanomedicine technology”70
October 2011
(Continued)
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Table 2 (Continued)
Nanoinformatics events and activities Date
Final specification of the nano-TAB standard November 2011
Nanoinformatics 2011, Arlington, VA December 2011
A Research Strategy for Environmental, Health, and Safety Aspects of Engineered Nanomaterials released.81  
National Research Council
January 2012
Launch of the ISA-TAB-Nano (first version), general purpose framework that provides a standard means to  
communicate data on nanomaterial properties and experiments. Nano working Group, National Cancer Institute
European Summit for Clinical Nanomedicine 2012. Basel, Switzerland April 2012
Future events
6th Concertation and Consultation workshop on Micro-Nano-Bio-Convergence Systems 2012.  
Athens, Greece. European Commission
May 2012
Nanofair 2012 – 9th International Nanotechnology Symposium. Dresden, Germany June 2012
8th NanoBio-Europe conference. Varese, Italy
NanoTech Conference and Expo 2012. Santa Clara, CA
9th International Conference on Nanosciences and Nanotechnologies (NN12). Thessaloniki, Greece July 2012
International Conference on Nanoscience + Technology (ICN+T2012). Paris, France
Nanoinformatics 2012 To be determined

















































































Figure 3 Timeline of events and activities depicted in Table 2.
Abbreviations: Biol Res, Biological Research; CSN, Collaboratory for Structural Nanobiology; IANH, International Alliance for NanoEHS Harmonization; ICON, International 
Council on Nanotechnology; ICN, International Conference on Nanoscience; MNBS, Micro-Nano-Bio Systems; NNI, National Nanotechnology Initiative; NNN, National 
Nanomanufacturing Network; NRC, National Research Council; NSTI, Nano Science and Technology Institute; NSF, National Science Foundation; PCAST, President’s 
Council of Advisors on Science and Technology.
anatomical structure. Figure 2 shows a screenshot of the pro-
totype of this engine, the Nanoparticles Toxicity Searcher, that 
we have developed. If the user is interested in discovering the 
toxic effects of QDs in cells as reported in the literature, they 
would type the keywords “quantum dots” and “cell” in the 
boxes labeled “Nanoparticle” and “Target.” Then, they would 
click the “Search” button, and the system would automatically 
retrieve all papers indexed by these keywords, as shown in the 
figure. The abstract and/or the full text of the articles can then 
be easily retrieved by clicking their corresponding PubMed 
identifiers or PMID hyperlinks, as shown.
Second, we have automated the recognition and extrac-
tion of mentions of nanotoxicology-related entities from 
the scientific literature. The targeted entities belong to four 
different categories: nanoparticles, routes of exposure, 
toxic effects, and potential targets. The entity recognizer 
was trained using a text corpus that we specifically created 
for this purpose and was validated by two nanomedicine/
nanotoxicology experts. The text corpus is composed of 
around 300 sentences  manually extracted from papers 
 available and indexed in PubMed, which were anno-
tated with relevant nanotoxicology entities. This kind of 
research can serve as a basis to stimulate further research 
on information retrieval and text mining – for example, 
for nanotoxicological purposes – as has occurred in areas 
such as BMI.
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These two projects can be viewed as early results  supporting 
our claims regarding the usefulness of  nanoinformatics efforts 
in indexing resources about nanotoxicity using information 
available from the literature. However, even if it were possible 
to automatically generate a database of toxic effects from 
current data, this would provide no annotation regarding data 
reliability or reproducibility. Future efforts combining this 
kind of data with others derived from interlaboratory studies, 
as well as robust techniques for analysis of data for method 
development and validation efforts, are needed to help make 
sense of the data that can be aggregated. Similarly, data cura-
tion will require wikis or other means to integrate and assess 
comment on search results, to help improve methods, models 
and techniques, and to demonstrate the utility, effectiveness, 
advantages, and risks of the enterprise. For such purposes, 
international collaborations among researchers with comple-
mentary expertise will be crucial.
Visual ontologies
Particle shape and design are fundamental in determining the 
characteristics of the biological and biophysical processes that 
involve them. There are reports of the influence of nanoparticle 
shape and design on their interaction with target tissues and of 
these characteristics involving altered biodistribution, cellular 
internalization, and trafficking, among other processes.46 In 
nanomedicine, the effect of particle shapes on these processes 
might play a significant role in future applications of nanopar-
ticles for drug delivery. We have carried out original research 
centered on the recognition of nanoparticle shape and its classi-
fication by means of new types of visual ontologies/taxonomies 
for shapes and structures.123 There are two subobjectives:
1. a new approach to the creation of visual taxonomies and 
ontologies of shapes and structures more suitable than 
classical ontologies to handle the types of graphical and 
volume components that appear in structures such as 
proteins, viruses, and nanoparticles
2. research techniques for pattern recognition of nanopar-
ticles and their automatic classification.
At this time, we have already implemented a prototype of 
a recognition system that can automatically identify specific 
shapes of nanoparticles in two dimensions. Further research will 
be needed to create a system that identifies the three- dimensional 
shapes of nanoparticles that can be used in practice.
In this regard, future applications might include the 
Material Genome Initiative (see the Appendix) or other 
projects involving information derived from both ligand and 
structural macromolecular databases.124 These applications 
might include models that could account for the different 
conformations of ligands and macromolecules in various 
physiological environments.
Ontologies or extensions of current terminologies (eg, 
Medical Subject Headings [MeSH]) can help to annotate or 
organize papers and experiments – as is done in the –omics 
area. For instance, papers can be better indexed in PubMed, 
improving search and access to the nano bibliography. Similarly, 
databases can be more effectively organized and curated. In this 
context, research on automated methods to create inventories 
of informatics resources in the nano areas can be beneficial, as 
we have shown previously in the bioinformatics area.105 Such 
nanoinformatics approaches can then facilitate access to differ-
ent types of information and help growth within the field.
Conclusion
Nanomedicine raises numerous challenges119,125 and requires 
significant investment in informatics to accelerate current 
research and developments. Such informatics requirements 
are related to what biomedical informaticians have already 
carried out in post-genomic research projects, which have 
transformed biomedical research. For nanotechnology, addi-
tional requirements are needed to accommodate the use of 
computational models and simulations, their range of valid-
ity, and increased sharing of codes, to rationally assimilate 
models from different disciplines and areas of research. In 
addition, nanoinformatics still needs a common agreement 
on the goals, subfields, research topics, training needs, and 
ethical requirements, which could lead to more specific 
agendas for research and development.
In this review, we have endeavored to illustrate illustrated 
major challenges and opportunities that research on nano-
informatics faces in advancing nanomedicine. Without such 
informatics methods and tools, developments will surely lag. 
In addition, Table 2 and Figure 3 show a timetable of the main 
events that have taken place in the area of nanoinformatics 
over the last few years. They show a slow but continuous 
development, with significant achievements, including con-
ferences, white papers, journal publications, and events.
In this paper we have also illustrated the needs of nano-
medicine, in terms of data and information management. 
We have also discussed some of the problems that nano-
informaticians face with examples of key areas related to 
current research projects carried out by the authors, showing 
the kinds of problems and approaches that can be adopted 
in nanoinformatics. Finally, the potential impact of nanoin-
formatics has been explored from  economic, scientific, and 
ethical perspectives, emphasizing the opportunities that inter-
national collaboration can provide to advance the field.
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Table A1 Summary of current nanoinformatics initiatives and projects
Name/acronym Description Institution Geographical area Start year
Initiatives and scientific networks
Nano Science and Technology  
Institute (NSTI)
It integrates nano and other  
technologies through education, 
conventions, business publishing,  
and research services
NSTI USA 1997
NanoBioTechnology Center Experts on nanobiotechnology:  
biomolecular devices, cellular  
microdynamics, cell–surface  
interactions, cell biology, etc
National Science Foundation (NSF) USA 2000
National Nanotechnology  
Initiative (NNI)
Central point of communication,  
cooperation, and collaboration for 
all US federal agencies engaged in  
nanotechnology research
25 US governmental agencies USA 2000
Global Nanotechnology  
Network
Platform for addressing shared  
global challenges through nanoscale 
science, engineering, development,  
and education
Diverse nanotechnology stakeholders  
from industry, academia, and  
government
International 2001
International Council on  
Nanotechnology (ICON)
Portal for information about the 
environmental, health, and safety 
aspects of nanotechnology
Rice University USA 2004
National Cancer Institute (NCI)  
Alliance for nanotechnology  
in Cancer
Committed to build a community  
of researchers dedicated to using 
nanotechnology to advance the  
fight against cancer
NCI, US National Institutes  
of Health (NIH)
USA 2004
Alliance for NanoHealth Promotes nano-based approaches, 
nano-resources, and tools to  
battle against cancer, heart  
diseases, or diabetes
Texas Medical Center  
(Houston, TX)
USA 2005
European Technology Platform  
on Nanomedicine
Led by industry together with the  
European Commission (EC) for  
the application of nanotechnology  
in health care
EC Europe 2005
Nanoforum European Nanotechnology  
Gateway
Former Fifth RTD Framework  





Nanomachinery of the cell to  
control and manipulate molecules 
and supramolecular assemblies  
in living cells
US NIH USA 2005
Nanotechnology  
Characterization Laboratory
A NCI-supported lab to perform  
and standardize nanomaterials  
intended for cancer therapeutics  
and diagnostics
NCI, US NIH USA 2005
Nanotechnologies  
Industries Association
It represents the industries’ views,  
interfaces with governments,  
consultation on regulation,  
standards, media and public
Group of companies from a  
variety of industry sectors
International 2005
Project on Emerging  
Nanotechnologies
Designed to minimize potential  
risks to health and environment,  
identifying gaps in knowledge  
and regulatory processes
Pew Charitable Trusts, woodrow  





This appendix presents a very large table listing the large number of initiatives and databases spanning the collecting, 
 gathering, curating, and providing of nano-related information for professionals and other nanotechnology users.
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Table A1 (Continued)
Name/acronym Description Institution Geographical area Start year
Safer Nanomaterials and  
Nanomanufacturing Initiative
New nanomaterials and  
nanomanufacturing approaches that  
offer a high level of performance,  
yet pose minimal harm
Universities of Oregon, Pacific  




Materials and new Production  
Technologies Programme
EC program which funds research, 
development, demonstration,  
and coordination projects
EC under FP7 Europe 2006
National Institute for  
Nanotechnology
Integrated, multidisciplinary,  
involves researchers in physics,  
chemistry, engineering, biology,  
informatics, and medicine
National Research Council of  
Canada and the University  
of Alberta
Canada 2006
National Network of  
Nanomedicine Development  
Centers
Initiative to determine the  
physical properties of cellular  
and subcellular components
US NIH USA 2006
SAFENANO Europe’s center of excellence on 
nanotechnology hazard and risk, 
facilitating responsible development  
of safe nanomaterials
Institute of Occupational  
Medicine (IOM)
Europe 2006
Technology cooperative  
framework on nanoscale  
analytical and measurement  
methods
Initiative for interlaboratory  
comparison on nanoparticle  
size. Characterization among ten  
laboratories from six member  
economies
Asia-Pacific Economy Cooperation  





ACTION-Grid International project on health care  
and nanoinformatics between Latin  
America, the western Balkans, and  
the European Union (EU)
EC under FP7 EU. Africa, USA,  
Latin America
2008
European Foundation for 
Clinical Nanomedicine
Initiative for prevention, diagnosis, 
and therapy through nanomedicine  
as well as exploration of  
its implications
Nonprofit institution, with  
researchers from the EU and USA
USA 2008
ICPCNanoNet Collaboration between  
organizations and scientists in the  
EU and International Cooperation  
Partner Countries (ICPC)
EC under FP7 EU and partner  
countries
2008
Institute of Electrical and  
Electronics Engineers (IEEE)  
Nanotechnology Council
IEEE group on nanotechnology IEEE International 2008
International Alliance for  
NanoEHS Harmonization
Scientists from the EU, Japan, and  
the USA to establish reproducible  
approaches for dealing with  
nanoparticle hazards
Peer-group of scientists that  
voluntarily collaborate
International  
(Europe, Japan,  
and the USA)
2008
NanoPediatrics Program Focused on the development and 
use of nanomedicine for the care  
of children
Mattel Children’s Hospital, University  
of California Los Angeles, CA
USA 2008
National Nanomanufacturing  
Network
Alliance of academic, government,  
and industry partners to promote  
nanomanufacturing workshops and  
exchanges
NSF USA 2008
Cancer Biomedical Informatics  
Grid (caBIG®) Nanotechnology  
working Group
Rational design of nanomaterials  
and discovering nanoparticle  
toxicity; development of standards  
and ontologies
NCI, US NIH USA 2009
EU Nanosafety Cluster EC’s initiative to maximize  
synergies between the Sixth 
Framework Programme (FP6) and  
Seventh Framework Programme  
(FP7) projects, addressing nanosafety
Compendium of EC-funded projects Europe 2009
(Continued)
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Ibero-American Network of  
Convergent Technologies for  
Health
Research on the social impact of  
converging technologies  
(Nano-Bio-Info-Cogno) in  
Ibero-America
Latin-American Science and  
Technology Development Programme
Latin America,  
Spain, and Portugal
2009
NanoCom To bridge the gap between  
laboratory-based and industrial  
applications in nanotechnology
EC through FP7. Coordinator:  
University of Nottingham
Europe 2009
Nanotechnology Informatics  
White Paper83
white paper covering the  
history of nanotechnology  
and the application of  
nanotechnology in the  
biomedical field
National Characterization  
Laboratory, US NCI
USA 2009
ObservatoryNano European observatory for  
science-based and economic expert 
analysis of nanotechnologies,
EC-FP7. Coordinator: Institute  
of Nanotechnology, UK
Europe 2009
MINAM 2.0 Brings together micro- and  
nano-related organizations
EC-FP7. Coordinator: Karlsruher  
Institut Für Technologie
Europe 2010
NanoGEM Evaluates the hazards of industrially  
relevant nanomaterials and  
nanoparticles contained in  
processed products
Institute of Energy and  
Environmental Technology
Germany 2010
ProNano Coaching services to research  
institutions or persons interested  
in the commercial exploitation of  
nanotechnologies
EC-FP7. Coordinator: Zabala  
Innovation Consulting, SA
Europe 2010
University of California Center  
for Environmental Implications  
of Nanotechnology
Development of environmental  
decision-making tools for managing  
engineered nanomaterials across a  
wide spectrum of nano/bio  
interfaces in cells, bacteria, etc
NSF, Environmental Protection  
Agency, California NanoSystems  
Institute, University of California
USA 2010
Materials Genome Initiative To develop an infrastructure to  
accelerate advanced materials  
discovery and deployment in the  
United States
National Science and  
Technology Council
USA 2011
Technology Platform  
NanoFutures
A European Technology Integrating  
and Innovation Platform,  
multi-sectorial
EC Europe 2011
Euro-Nano-Tox Portal for researchers and industry  





Data repositories and standards
ICON Environmental, Health  
and Safety Database
Contains summaries (abstracts)  
and citations
Rice University, ICON USA 2004
Molecular Imaging and Contrast  
Agent Database (MICAD)
Online source of scientific  
information regarding molecular  
imaging and contrast agents
NCBI, US NIH USA 2004
Nanotechnology Standards Panel Development of standards  
in nanotechnology including  
nomenclature/terminology;  
materials properties and testing
American National  
Standards Institute
USA 2004
ISO TC 229 Developing standards for the  
understanding and control of matter  
and processes at the nanoscale to  
create improved materials
International Association for  
Standardization (ISO)
International 2005
National Toxicology  
Program Database
Toxicology information about  
chemicals and nanoscale materials, 
abstracts, reports, and data from  
toxicology studies
NIH, National Institute for  
Occupational Safety and Health  
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American Society for Testing  
and Materials (ASTM)  
Nanotechnology
ASTM standards for nanotechnology  
as well as nanotechnology  
terminology, property testing,  
and issues of health and safety
ASTM USA 2006
caNanoLab Database Annotation of nanomaterials with  
characterizations resulting from  
physico-chemical and in vitro assays
NCI, US NIH USA 2006
SAFENANO Database Data resource on nanotechnology 
hazard and risk
IOM UK 2006
Organisation for Economic  
Co-operation and Development  
(OECD) Database on Research  
into Safety of Manufactured  
Nanomaterials
Collects research projects that  
address environmental, human  
health, and safety issues of  
manufactured nanomaterials
OECD International 2007
British Standards Institute (BSI)  
Nanotechnology
Documents relevant to  
nanotechnology, addressing  
nanotechnology terminology,  
health and safety issues, and  
product labeling
BSI UK 2008
Collaboratory for Structural  
Nanobiology
Nanoparticle structure files and  
related research data, as well as  
resources for the visualization of  
nanoparticles
NCI, US NIH, Universidad de  
Talca (Chile)
USA, Latin America 2008
ISO Nano Terminology It lists unambiguous terms and  
definitions related to particles  
in the field of nanotechnologies
ISO International 2008
MINChar A community initiative to improve  
the utility of nanotoxicology  
studies through effective  
nanomaterial characterization
The Dow Chemical Company, Evonik  
Industries, Rice University, ICON,  
BASF Corporation, NIOSH, Clemson  
University, woodrow wilson  
International Center for Scholars,  
National Institute of Environmental  
Health Sciences (NIEHS), DuPont
USA 2008
NanoParticle Ontology An ontology with basic physical,  
chemical and functional nano  
characteristics, as used in cancer  
diagnosis and therapy
caBIG USA 2008
Cancer Open Biomedical  
Resource Project
Toolset for information retrieval  
for cancer nanotechnology-related 
information using biomedical  
ontologies
National Center for Biomedical  
Ontology through US NIH (NIH)
USA 2009
Nanomaterials Registry Public resource of curated  
information on biological and  
environmental interactions of  
nanomaterials
NIBIB, NIEHS, NCI USA 2009
Nanoparticle Information  
Library
Nanoparticle library to organize  
and share information on  
nanomaterials, including health  
and safety-associated properties
NIOSH USA 2009
Nano-TAB Data-sharing challenges in  
nanotechnology by identifying  
nanomaterials and characterizations 
in a tab-delimited format
NCI, US NIH USA 2009
DaNa Acquisition, evaluation, and  
public-oriented presentation  
of society-relevant data and  
findings relating to nanomaterials
DECHEMA eV Germany 2010
(Continued)
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Nanomaterial-Biological  
Interactions Knowledgebase
Repository for annotated data  
on nanomaterial characterization  
synthesis methods and  
nanomaterial–biological interactions
Oregon universities and  
Microtechnologies Institute
USA 2010
Nano-QSAR Initiative for applying structure– 
activity relationships (SARs) to  
predict properties of nanomaterials
NCI, US NIH USA 2010
European Repository of  
Reference Nanomaterials
Nanomaterial repository with a  
collection representing 25  
different types of nanomaterials
EC’s Joint Research Centre Europe 2011
InterNano NanoManufacturing  
Taxonomy
Central digital repository of  
nanomanufacturing research and  
trade information for the  
nanomanufacturing community





Standard format for representing  
information on nanomaterials and  
small molecules along with their  
assay characterization data
NCI, US NIH USA 2012
Collaborative platforms
Network for Computational  
Nanotechnology (NCN)
Cyber-resource for  
nanotechnology theory,  
modeling, and simulation
NSF USA 2002
Nano Network Consortium of resources  
available to companies
ONAMI USA 2003
caNanoLab Data-sharing portal designed to  
facilitate information sharing in  
the biomedical nanotechnology  
research community
NCI, US NIH USA 2006
InterNano Information clearinghouse for the 
nanomanufacturing community
Coordinated by the National  
Nanomanufacturing Network  
and funded by the NSF
USA 2007
NANOSAFE Inc An extensive network of experts  
in the fields of nanoscience  
and engineering, industrial and  
environmental health and safety,  
toxicology, and risk assessment
Virginia Tech Corporate Research  
Center’s Knowledgeworks Business  
Accelerator
USA 2007
GoodNanoGuide Collaboration platform designed  
to enhance the ability of experts  
to exchange ideas on how best  
to handle nanomaterials
Rice University USA 2009
NanoHub – NCN Framework with a set of tools  
for online simulation and more  
for nanotechnology
NSF USA 2009
QNano EU-funded infrastructure for  
nanomaterial safety testing
EC through FP7 Europe 2011
Dissemination and information portals
Nano Tech wire Latest nanotechnology news NNI, NSTI, FEI Company,  
Veeco, Zyvex
USA 2003
ICON nanoEHS Virtual Journal The Virtual Journal of  
Nanotechnology Environment, 
Health and Safety
Rice University, ICON (ICON) USA 2004
Nanowerk Committed to educating, informing,  
and inspiring people about  
nanosciences and nanotechnologies
Nanowerk LLC USA 2005
PEN Environmental, Health  
and Safety Inventory
An inventory of current research 
involving nanotechnology health  
and environmental implications
Pew Charitable Trusts, woodrow  
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PEN Nanotechnology  
Medical Applications
web-based resource to better  
understand current and future  
applications of nanotechnology  
in various fields of medicine
Pew Charitable Trusts, woodrow  
wilson International Center for  
Scholars
USA 2005
TryNano Information resource for anyone  
interested in learning about  
nanoscience and nanotechnology,  
oriented to the general public
IBM, IEEE, New York Hall  
of Science
International 2007
Nanotechnology Risk  
Resources
References to papers, articles,  
and books on (or related to)  
potential health and environmental  
risks of nanomaterials
Nanotechnology Citizens  
Engagement Organization
USA 2010
National Institute of Standards  
and Technology (NIST)  
Nanotechnology Portal
Portal about nanotechnology- 
related research conducted in  
NIST’s laboratories that develops  
measurements and standards
NIST USA 2010
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